Thursday, May 21, 2026 7:29:58 PM
LOL, you left off the important part from a search of "M&A transaction at Jefferies takes about 6 to 9 months" -
A typical Mergers & Acquisitions (M&A) transaction advised by investment banks like Jefferies generally spans 6 to 9 months, from the initial pitch to the final closing. However, complex deals can easily stretch out to a year or longer, depending on buyer availability and regulatory requirements.
WHY did you not post the whole AI answer??? You have an objective on this board? Creating FUD???
Posted the below the other day and you went crazy, now here you posting selective copy/paste from an AI search.
My post - A major company acquisition typically takes 6 to 18 months from the initial offer to the final closing. Deals exceeding $500 million can stretch past a year due to complex financing, extensive due diligence, and required antitrust/regulatory approvals.
I, ME, Myself believe that Elite will sell for $1BILLION or more and with the potential of submitting a generic Eliquis, the IP for SequestOX, and other complex negotiations the acquisition will take longer than 9 months. Be patient and chill as all of us longs' investment in ELITE will pay off HUGE! Or, since you may be a foreign short that is part of a dark pool, go ahead and panic some more, LOL!!!
A typical Mergers & Acquisitions (M&A) transaction advised by investment banks like Jefferies generally spans 6 to 9 months, from the initial pitch to the final closing. However, complex deals can easily stretch out to a year or longer, depending on buyer availability and regulatory requirements.
WHY did you not post the whole AI answer??? You have an objective on this board? Creating FUD???
Posted the below the other day and you went crazy, now here you posting selective copy/paste from an AI search.
My post - A major company acquisition typically takes 6 to 18 months from the initial offer to the final closing. Deals exceeding $500 million can stretch past a year due to complex financing, extensive due diligence, and required antitrust/regulatory approvals.
I, ME, Myself believe that Elite will sell for $1BILLION or more and with the potential of submitting a generic Eliquis, the IP for SequestOX, and other complex negotiations the acquisition will take longer than 9 months. Be patient and chill as all of us longs' investment in ELITE will pay off HUGE! Or, since you may be a foreign short that is part of a dark pool, go ahead and panic some more, LOL!!!
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/01/2026 11:00:24 AM
- Elite Pharmaceuticals Announces Filing of Abbreviated New Drug Application with the U.S. Food and Drug Administration for Generic Anticoagulant Product • Newsfile • 06/01/2026 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:05:23 PM
- Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets • Newsfile • 04/02/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 10:10:32 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information • Newsfile • 02/17/2026 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:06:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:35:26 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026 • Newsfile • 02/11/2026 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:35:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:23 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information • Newsfile • 11/14/2025 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:11:38 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/12/2025 10:19:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 12:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 12:15:46 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025 • Newsfile • 11/10/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2025 09:17:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/22/2025 01:39:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2025 08:37:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 08:35:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2025 10:05:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2025 08:17:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2025 08:15:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/08/2025 02:58:10 PM
